Literature DB >> 17882457

Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis.

Kerstin Benz1, Kerstin Amann, Katalin Dittrich, Jörg Dötsch.   

Abstract

We report on a 12-year-old female patient with steroid-dependent nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) since her 3rd year of life. She was twice treated with oral cyclophosphamide and received antihypertensive treatment with atenolol and enalapril. After 3 years without any control or therapy, she presented in a reduced general condition with hypertensive crisis and a blood pressure of 220/130 mmHg, headache, vomiting and loss of vision. Additionally, renal insufficiency (creatinine 11.4 mg/dl, urea 157 mg/dl), with oliguria, anaemia and a severe relapse of nephrotic syndrome, was present. Initial treatment with steroids, albumin-furosemide infusions and antihypertensive drugs was unsuccessful, and dialysis treatment was necessary. Renal biopsy showed an advanced stage of the known FSGS and, surprisingly, a thrombotic microangiopathy. Further diagnostic investigations revealed no signs of haemolytic-uraemic syndrome, but echocardiography showed left ventricular hypertrophy, and hypertensive retinopathy grade 3 was diagnosed, making severe hypertension the most likely reason for the thrombotic microangiopathy. While adequate antihypertensive treatment led to regress of left ventricular hypertrophy and hypertensive retinopathy, renal function did not recover, and the patient remained dialysis-dependent. In conclusion, severe hypertension in chronic kidney disease can lead to target organ damage and thrombotic microangiopathy, which may further worsen renal function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882457     DOI: 10.1007/s00467-007-0563-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?

Authors:  Yugo Shibagaki; Toshiro Fujita
Journal:  Hypertens Res       Date:  2005-01       Impact factor: 3.872

Review 2.  The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases.

Authors:  R Habib; C Kleinknecht
Journal:  Pathol Annu       Date:  1971

Review 3.  Nephrosclerosis and hypertension.

Authors:  H Ono; Y Ono
Journal:  Med Clin North Am       Date:  1997-11       Impact factor: 5.456

Review 4.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

5.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

6.  The clinical presentation of malignant hypertension in Nigerians.

Authors:  S Kadiri; B O Olutade
Journal:  J Hum Hypertens       Date:  1991-08       Impact factor: 3.012

7.  End-stage renal disease from glomerulonephritis associated with anti-phospholipid syndrome.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2004-05-06       Impact factor: 3.714

8.  The long-term prognosis of patients with focal segmental glomerulosclerosis.

Authors:  J S Cameron; D R Turner; C S Ogg; C Chantler; D G Williams
Journal:  Clin Nephrol       Date:  1978-12       Impact factor: 0.975

Review 9.  Cyclosporine in the treatment of idiopathic nephrosis.

Authors:  P Niaudet; R Habib
Journal:  J Am Soc Nephrol       Date:  1994-10       Impact factor: 10.121

10.  Blood pressure and end-stage renal disease in men.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; C E Ford; N B Shulman; J Stamler
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

View more
  3 in total

1.  Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.

Authors:  Rachel C Challis; Troels Ring; Yaobo Xu; Edwin K S Wong; Oliver Flossmann; Ian S D Roberts; Saeed Ahmed; Michael Wetherall; Giedrius Salkus; Vicky Brocklebank; Julian Fester; Lisa Strain; Valerie Wilson; Katrina M Wood; Kevin J Marchbank; Mauro Santibanez-Koref; Timothy H J Goodship; David Kavanagh
Journal:  J Am Soc Nephrol       Date:  2016-12-14       Impact factor: 10.121

2.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

3.  Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy.

Authors:  Kentaro Nishi; Mai Sato; Masao Ogura; Mika Okutsu; Kenji Ishikura; Koichi Kamei
Journal:  BMC Nephrol       Date:  2020-08-03       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.